Therefore, the aCDase inhibitor, LCL204, which can sensitize HNSCC cells to Fas-induced apoptosis in vitro and in vivo, could be a therapeutic agent for HNSCC (Section 6.1). Here, FAS is linked to head and neck squamous cell carcinoma.